Cargando…

P2Y(12) Receptor Inhibitors in Acute Coronary Syndromes: What Is New on the Horizon?

Dual antiplatelet therapy with aspirin and a P2Y(12) receptor inhibitor represents the cornerstone therapy for patients with acute coronary syndromes or undergoing percutaneous interventions, leading to a reduction of subsequent ischemic events. Variable response to clopidogrel has received close at...

Descripción completa

Detalles Bibliográficos
Autores principales:	Oprea, Adriana Dana, Popescu, Wanda M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi Publishing Corporation 2013
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3590496/ https://www.ncbi.nlm.nih.gov/pubmed/23533940 http://dx.doi.org/10.1155/2013/195456

Ejemplares similares

De-Escalation of P2Y(12) Receptor Inhibitor Therapy after Acute Coronary Syndromes in Patients Undergoing Percutaneous Coronary Intervention
por: Kupka, Danny, et al.
Publicado: (2018)

Protease‐activated receptor‐mediated platelet aggregation in acute coronary syndrome patients on potent P2Y(12) inhibitors
por: Wadowski, Patricia P., et al.
Publicado: (2019)

Pretreatment with P2Y(12) Receptor Inhibitors in Acute Coronary Syndromes—Is the Current Standpoint of ESC Experts Sufficiently Supported?
por: Niezgoda, Piotr, et al.
Publicado: (2023)

De-escalation of P2Y12 Inhibitor Use After Percutaneous Coronary Intervention and Acute Coronary Syndromes
por: Barry, Quinton, et al.
Publicado: (2021)

Ideal P2Y12 Inhibitor in Acute Coronary Syndrome: A Review and Current Status
por: Pradhan, Akshyaya, et al.
Publicado: (2022)

What Is on the Horizon?
por: Nair, P. N. Ramachandran
Publicado: (2014)

P2Y12 Inhibitor Monotherapy with Clopidogrel versus Ticagrelor in Patients with Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention
por: Chen, Po-Wei, et al.
Publicado: (2020)

Dysregulation in the Expression of Platelet Surface Receptors in Acute Coronary Syndrome Patients—Emphasis on P2Y12
por: Szelenberger, Rafał, et al.
Publicado: (2022)

Systematic reviews: causes of non-adherence to P2Y12 inhibitors in acute coronary syndromes and response to intervention
por: Johnston, Nina, et al.
Publicado: (2016)

Efficacy and safety of newer P2Y(12) inhibitors for acute coronary syndrome: a network meta-analysis
por: Fei, Yue, et al.
Publicado: (2020)

Platelet CD40 ligand and bleeding during P2Y12 inhibitor treatment in acute coronary syndrome
por: Grosdidier, Charlotte, et al.
Publicado: (2019)

Efficacy and safety of potent P2Y12 inhibitors vs. clopidogrel in elderly patients with acute coronary syndrome
por: Luo, Li-Man, et al.
Publicado: (2020)

Comparative Risk of Hospitalized Bleeding of P2Y12 Inhibitors for Secondary Prophylaxis in Acute Coronary Syndrome After Percutaneous Coronary Intervention
por: Kumar, Arun, et al.
Publicado: (2022)

Association between P2Y12 inhibitor reloading and in-hospital outcomes for patients with non-ST-segment elevation acute coronary syndrome already on chronic P2Y12 receptor inhibitors therapy in China: findings from the CCC–ACS (improving care for cardiovascular disease in China-acute coronary syndrome) project
por: Wang, Yintang, et al.
Publicado: (2023)

A pharmacodynamic study of the optimal P2Y(12) inhibitor regimen for East Asian patients with acute coronary syndrome
por: Lee, Ji Hyun, et al.
Publicado: (2015)

Orthodontic retention: what's on the horizon?
por: Littlewood, Simon J., et al.
Publicado: (2021)

P2Y(12) Inhibitor Pre-Treatment in Non-ST-Elevation Acute Coronary Syndrome: A Decision-Analytic Model
por: Gunton, James, et al.
Publicado: (2016)

P2Y12 inhibitor pretreatment in patients with nonST-segment elevation acute coronary syndrome: A meta-analysis
por: Yan, Longhui, et al.
Publicado: (2022)

P2Y12 Inhibitors in Acute Coronary Syndromes: A Real-World, Community-Based Comparison of Ischemic and Bleeding Outcomes
por: Sachdeva, Amit, et al.
Publicado: (2023)

Differences in Optimal Platelet Reactivity after Potent P2Y12 Inhibitor Treatment in Acute Coronary Syndrome Patients Undergoing Percutaneous Coronary Intervention
por: Song, Kai, et al.
Publicado: (2022)

Association of Pretreatment With P2Y12 Receptor Antagonists Preceding Percutaneous Coronary Intervention in Non–ST-Segment Elevation Acute Coronary Syndromes With Outcomes
por: Dworeck, Christian, et al.
Publicado: (2020)

Resistance on the Latest Oral and Intravenous P2Y12 ADP Receptor Blockers in Patients with Acute Coronary Syndromes: Fact or Myth?
por: Blaško, Peter, et al.
Publicado: (2022)

Contemporary use of P2Y12-inhibitors in patients with acute coronary syndrome undergoing percutaneous coronary intervention in Austria: A prospective, multi-centre registry
por: Tscharre, Maximilian, et al.
Publicado: (2017)

P2Y(12) Inhibitor Monotherapy after Percutaneous Coronary Intervention
por: Zhou, Xuan, et al.
Publicado: (2022)

Novel Oral P2Y12 Inhibitor Prasugrel vs. Clopidogrel in Patients with Acute Coronary Syndrome: Evidence Based on 6 Studies
por: Jia, Min, et al.
Publicado: (2015)

Impact of the Dual Antiplatelet Therapy Score on Clinical Outcomes in Acute Coronary Syndrome Patients Receiving P2Y12 Inhibitor Monotherapy
por: Huang, Sheng-Wei, et al.
Publicado: (2022)

The Impact of Preclinical High Potent P2Y(12) Inhibitors on Decision Making at Discharge and Clinical Outcomes in Patients with Acute Coronary Syndrome
por: Hammer, Andreas, et al.
Publicado: (2023)

Impact of body mass on P2Y12-inhibitor de-escalation in acute coronary syndromes—a substudy of the TROPICAL-ACS trial
por: Komócsi, András, et al.
Publicado: (2023)

P2Y12 Inhibitor Monotherapy versus Conventional Dual Antiplatelet Therapy in Patients with Acute Coronary Syndrome after Percutaneous Coronary Intervention: A Meta-Analysis
por: Feng, Wen-Han, et al.
Publicado: (2023)

P2Y(12) Platelet Receptors: Importance in Percutaneous Coronary Intervention
por: Falcão, Felipe Jose de Andrade, et al.
Publicado: (2013)

Sex-Related Bleeding Risk in Acute Coronary Syndrome Patients Receiving Dual Antiplatelet Therapy with Aspirin and a P2Y12 Inhibitor
por: ten Haaf, Monique E., et al.
Publicado: (2023)

Intolerance to Multiple P2Y12 Inhibitors Following Percutaneous Coronary Intervention
por: Shnoda, Mina, et al.
Publicado: (2021)

Biomarkers for hepatocellular carcinoma: What’s new on the horizon?
por: Ocker, Matthias
Publicado: (2018)

What is new on the horizon in melanoma brain metastasis?
por: Margolin, Kim
Publicado: (2019)

Beyond kidney dialysis and transplantation: what’s on the horizon?
por: Rabb, Hamid, et al.
Publicado: (2022)

Safety and Effectiveness of Contemporary P2Y(12) Inhibitors in an East Asian Population With Acute Coronary Syndrome: A Nationwide Population‐Based Cohort Study
por: Yun, Ji Eun, et al.
Publicado: (2019)

Comparative efficacy and safety of oral P2Y(12) inhibitors after non-ST-elevation acute coronary syndromes: a network meta-analysis
por: Farmakis, Ioannis T, et al.
Publicado: (2022)

Effect of aspirin treatment duration on clinical outcomes in acute coronary syndrome patients with early aspirin discontinuation and received P2Y12 inhibitor monotherapy
por: Ho, Ming-Yun, et al.
Publicado: (2021)

Indications for Proning in Acute Respiratory Distress Syndrome: Expanding the Horizon!
por: Lalwani, Lokesh K, et al.
Publicado: (2020)

Effect of pretreatment with a P2Y(12) inhibitor in patients with non-ST-elevation acute coronary syndrome: a systematic review and network meta-analysis
por: Li, Yachao, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_9ckmbasg5q9sn3jfea4se3jik1